Stoke Therapeutics (NASDAQ:STOK) Stock Price Expected to Rise, Wedbush Analyst Says

Stoke Therapeutics (NASDAQ:STOK) had its target price raised by research analysts at Wedbush from $32.00 to $36.00 in a report issued on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush’s price target indicates a potential upside of 9.59% from the company’s current price.

Other analysts have also recently issued reports about the company. UBS Group set a $50.00 target price on Stoke Therapeutics in a research report on Monday, December 15th. Needham & Company LLC increased their price objective on Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a report on Friday, October 10th. HC Wainwright raised their target price on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. JPMorgan Chase & Co. lifted their target price on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a report on Monday, November 3rd. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Stoke Therapeutics in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Stoke Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $37.10.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK opened at $32.85 on Monday. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $38.69. The firm has a market capitalization of $1.88 billion, a P/E ratio of 49.03 and a beta of 1.10. The company’s fifty day moving average price is $30.17 and its 200 day moving average price is $23.82.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The company had revenue of $10.63 million during the quarter, compared to analyst estimates of $6.06 million. On average, sell-side analysts anticipate that Stoke Therapeutics will post -2.01 EPS for the current year.

Insiders Place Their Bets

In related news, General Counsel Jonathan Allan sold 8,785 shares of the stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $31.29, for a total transaction of $274,882.65. Following the transaction, the general counsel directly owned 15,809 shares in the company, valued at approximately $494,663.61. This represents a 35.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Adrian R. Krainer sold 40,472 shares of the firm’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $26.98, for a total value of $1,091,934.56. Following the completion of the sale, the director directly owned 364,246 shares in the company, valued at approximately $9,827,357.08. The trade was a 10.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 104,705 shares of company stock worth $3,070,910. 9.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Corient Private Wealth LLC purchased a new stake in Stoke Therapeutics in the second quarter valued at approximately $7,489,000. Wellington Management Group LLP boosted its holdings in shares of Stoke Therapeutics by 438.2% in the 3rd quarter. Wellington Management Group LLP now owns 737,753 shares of the company’s stock valued at $17,337,000 after purchasing an additional 600,687 shares during the last quarter. Polar Capital Holdings Plc grew its stake in shares of Stoke Therapeutics by 49.8% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock valued at $31,102,000 after buying an additional 439,824 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Stoke Therapeutics by 67.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 900,272 shares of the company’s stock worth $21,156,000 after buying an additional 362,299 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Stoke Therapeutics by 21.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after buying an additional 293,072 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.